Johnson & Johnson (NYSE:JNJ) Shares Bought by Breakwater Capital Group

Breakwater Capital Group lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 7,818 shares of the company’s stock after acquiring an additional 899 shares during the period. Breakwater Capital Group’s holdings in Johnson & Johnson were worth $1,237,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Alerus Financial NA raised its stake in shares of Johnson & Johnson by 1.7% during the third quarter. Alerus Financial NA now owns 4,299 shares of the company’s stock valued at $670,000 after purchasing an additional 71 shares in the last quarter. Elevatus Welath Management raised its position in shares of Johnson & Johnson by 29.1% during the 3rd quarter. Elevatus Welath Management now owns 1,802 shares of the company’s stock worth $281,000 after buying an additional 406 shares in the last quarter. Legacy Advisors LLC lifted its stake in shares of Johnson & Johnson by 6.3% in the 3rd quarter. Legacy Advisors LLC now owns 72,571 shares of the company’s stock worth $11,303,000 after acquiring an additional 4,279 shares during the period. Lakeshore Financial Planning Inc. bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $460,000. Finally, KPP Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at approximately $1,828,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $146.42 on Tuesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a market cap of $352.39 billion, a PE ratio of 9.13, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52. The business has a fifty day simple moving average of $148.14 and a 200-day simple moving average of $154.05.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.68 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s payout ratio is currently 30.92%.

Analyst Ratings Changes

A number of equities analysts have issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.